Randomized Angioplasty Beta Blocker Given Intracoronary Trial II. A trial that evaluated intracoronary administration of a beta-blocker (propranolol) in patients undergoing percutaneous coronary intervention also treated with glycoprotein (GP) IIb/IIIa inhibitors
Conclusion In patients undergoing PCI also treated with GP IIb/IIIa inhibitors, IC administration of propranolol was associated with a reduction in the frequency of post-PCI MI compared to placebo